fda approved glp-1 receptor agonists glp 1 drugs What to Make of the Coverage and Cost Landscape of GLP-1RAs approved for the
Description
[31] observed a significantly higher incidence of increased RGC in patients treated with weekly GLP-1 RAs (semaglutide, dulaglutide, or tirzepatide) compared with control patients, with no correlation between the duration of drug discontinuation (up to seven days) and RGC levels

December 2023: Judge James Cain, Jr

Exploring the mechanisms of receptor synergy and its influence on weight loss and glycemic control could help in designing more targeted and potent agonists

Oral option needed: Only Semaglutide has an oral form (Rybelsus), though injectables outperform it for weight loss
